JP2019514913A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514913A5
JP2019514913A5 JP2018556332A JP2018556332A JP2019514913A5 JP 2019514913 A5 JP2019514913 A5 JP 2019514913A5 JP 2018556332 A JP2018556332 A JP 2018556332A JP 2018556332 A JP2018556332 A JP 2018556332A JP 2019514913 A5 JP2019514913 A5 JP 2019514913A5
Authority
JP
Japan
Prior art keywords
agent
optionally
polypeptide
antibody
adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018556332A
Other languages
English (en)
Japanese (ja)
Other versions
JP7160683B2 (ja
JP2019514913A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/030454 external-priority patent/WO2017190148A1/en
Publication of JP2019514913A publication Critical patent/JP2019514913A/ja
Publication of JP2019514913A5 publication Critical patent/JP2019514913A5/ja
Application granted granted Critical
Publication of JP7160683B2 publication Critical patent/JP7160683B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018556332A 2016-04-29 2017-05-01 術後癒着の予防及び治療のための方法及び組成物 Active JP7160683B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329666P 2016-04-29 2016-04-29
US62/329,666 2016-04-29
PCT/US2017/030454 WO2017190148A1 (en) 2016-04-29 2017-05-01 Methods and compositions for the prevention and treatment of surgical adhesions

Publications (3)

Publication Number Publication Date
JP2019514913A JP2019514913A (ja) 2019-06-06
JP2019514913A5 true JP2019514913A5 (OSRAM) 2020-05-28
JP7160683B2 JP7160683B2 (ja) 2022-10-25

Family

ID=60161169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556332A Active JP7160683B2 (ja) 2016-04-29 2017-05-01 術後癒着の予防及び治療のための方法及び組成物

Country Status (9)

Country Link
US (1) US10934355B2 (OSRAM)
EP (1) EP3448421B1 (OSRAM)
JP (1) JP7160683B2 (OSRAM)
CA (1) CA3019841A1 (OSRAM)
ES (1) ES2903210T3 (OSRAM)
PL (1) PL3448421T3 (OSRAM)
PT (1) PT3448421T (OSRAM)
SI (1) SI3448421T1 (OSRAM)
WO (1) WO2017190148A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
AU2019349651B2 (en) 2018-09-27 2023-12-07 Celgene Corporation SIRP alpha binding proteins and methods of use thereof
WO2020157122A1 (en) 2019-01-29 2020-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
US20200386772A1 (en) * 2019-06-05 2020-12-10 Mark D. Noar Method For Detecting Bodily Adhesions By Identifying Markers In Circulating Cells
CN113304131B (zh) * 2020-02-26 2022-10-18 上海科技大学 多酚类物质在抗冠状病毒中的应用
WO2022126259A1 (en) * 2020-12-14 2022-06-23 Uti Limited Partnership Treatment of peritoneal, pleural, and pericardium adhesions
US12011163B2 (en) 2021-01-22 2024-06-18 Cilag Gmbh International Prediction of tissue irregularities based on biomarker monitoring
US12440285B2 (en) 2021-01-22 2025-10-14 Cilag Gmbh International Prediction of hemostasis issues based on biomarker monitoring
US20220233135A1 (en) * 2021-01-22 2022-07-28 Ethicon Llc Prediction of adhesions based on biomarker monitoring
CN113244400B (zh) * 2021-05-21 2022-12-16 华北理工大学 一种C5aRA在制备治疗和/或预防腹腔粘连的产品中的应用
KR20240099431A (ko) * 2021-11-05 2024-06-28 헬름홀츠 젠트룸 뮌헨-도이체스 포르슝스젠트룸 퓌르 게준드하이트 운트 움벨트 게엠베하 중피 ecm 이동의 조절제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639468A (en) 1995-06-07 1997-06-17 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof
JP2001520201A (ja) * 1997-10-16 2001-10-30 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 癒着形成の予防と処置
US6812220B2 (en) * 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
US20050163781A1 (en) * 2002-01-29 2005-07-28 Philippe Koninckx Tissue adhesion formation control
US20040131600A1 (en) * 2002-03-11 2004-07-08 Diamond Michael P. Method of preventing adhesions by apoptosis of adhesion peritoneal cells
JP4224586B2 (ja) * 2004-04-28 2009-02-18 国立大学法人群馬大学 マクロファージ活性化剤並びにその製造方法及びスクリーニング方法
CA2585268A1 (en) * 2004-10-25 2006-05-04 Ajay Verman Methods for lowering hif-1 mediated gene expression
AU2006223301B2 (en) * 2005-03-10 2010-11-04 Eisai, Inc. Anti-mesothelin antibodies
JP5329949B2 (ja) * 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
PL1940439T3 (pl) * 2005-08-11 2011-04-29 Univ Saskatchewan Zmniejszanie tworzenia pooperacyjnych zrostów przez dootrzewnowe podawanie glutaminy
CA2658584A1 (en) * 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
AU2008308956B2 (en) * 2007-10-01 2013-03-14 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
ES2735144T3 (es) 2008-01-15 2019-12-16 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
ES2325724B1 (es) * 2008-03-11 2010-05-31 FUNDACION DE LA COMUNIDAD VALENCIANA "CENTRO DE INVESTIGACIONES PRINCIPE FELIPE" Composicion farmaceutica para inhibir el factor de transcripcion inducible por hipoxia. moduladores de procesos patologicos de angiogenesis, oncogenesis, inflamacion, apoptosis y terapia celular.
US8460660B2 (en) * 2009-03-24 2013-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
US8758750B2 (en) 2009-09-15 2014-06-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
JP2011195574A (ja) * 2010-02-25 2011-10-06 Kwansei Gakuin ビスフェノールa誘導体を含有するhif阻害剤
SMT202000689T1 (it) 2012-01-17 2021-01-05 Univ Leland Stanford Junior Reagenti per sirp-alfa ad alta affinita'
US8962577B2 (en) * 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
ES2728066T3 (es) 2013-03-15 2019-10-22 Univ Leland Stanford Junior Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47

Similar Documents

Publication Publication Date Title
JP2019514913A5 (OSRAM)
Maini et al. Beneficial effects of tumour necrosis factor-alpha (TNF-α) blockade in rheumatoid arthritis (RA)
JP2006525796A5 (OSRAM)
Kobayashi Neutrophil infiltration and chemokines
Wiersinga et al. Host innate immune responses to sepsis
EP3448421B1 (en) Methods and compositions for the prevention and treatment of surgical adhesions
Canavan et al. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review
JP2006513992A5 (OSRAM)
JP2011519277A5 (OSRAM)
US20170020917A1 (en) Process for the identification of compounds for treating cancer
EP3606559A1 (en) Bioorthogonal compositions
JP2013100314A5 (OSRAM)
Atluri et al. Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder
Cirelli et al. AAV2/1-TNFR: Fc gene delivery prevents periodontal disease progression
Chen et al. Age-related alterations in immune function and inflammation: focus on ischemic stroke
JP2013504603A5 (OSRAM)
Thierry et al. NETs by-products and extracellular DNA may play a key role in COVID-19 pathogenesis: incidence on patient monitoring and therapy
Zhu et al. Low‐intensity pulsed ultrasound alleviates doxorubicin‐induced cardiotoxicity via inhibition of S100a8/a9‐mediated cardiac recruitment of neutrophils
JP2010513308A (ja) 血管新生向性ペプチド
Saito et al. The CC chemokine ligand (CCL) 1, upregulated by the viral transactivator Tax, can be downregulated by minocycline: possible implications for long-term treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis
Cai et al. The role of fibroblast-neutrophil crosstalk in the pathogenesis of inflammatory diseases: a multi-tissue perspective
CN114533720A (zh) Cd36抑制剂在制备抑制脊髓损伤后疤痕形成药物中的应用
Chen et al. Shenqi fuzheng injection improves cvb3-induced myocarditis via inhibiting traf6 expression
JP2007534772A5 (OSRAM)
Makowska et al. Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist